3 International Drive, Suite 200
Rye Brook, NY 10573
The Leukemia & Lymphoma Society (LLS) is the largest voluntary health organization dedicated to funding research, finding cures and ensuring access to treatments for blood cancer patients. For more than 65 years LLS has invested more than $1B to advance cancer therapies and save lives.
The Therapy Acceleration Program (TAP) is a strategic initiative to accelerate the development of innovative blood cancer treatments, supportive care and diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need.
TAP funding assists both clinical investigators and companies in gaining critical clinical proof of concept data that better enables them to obtain future resources or a partner. TAP will also help potential partners in setting development strategy, clinical site and PI selection, and physician/patient education about the clinical trials through LLS broad access to KOLs in blood cancers and its patient services/advocacy. TAP funding is different from the traditional grant at LLS. The TAP review process is open year round and is separate from the grant process. Each approved project is closely monitored by TAP staff.
LLS also provide various types of research grants to researchers at academic institutions. For more de-tails please visit http://www.lls.org/academic-grants.